Additional file 3 of Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
- Resource Type
- Authors
- Cottin, Vincent; Martinez, Fernando J.; Jenkins, R. Gisli; Belperio, John A.; Kitamura, Hideya; Molina-Molina, Maria; Tschoepe, Inga; Coeck, Carl; Lievens, Dirk; Costabel, Ulrich
- Source
- Subject
- Language
Additional file 3: Table S2. Dose reductions, treatment interruptions and exposure over 52 weeks in the INBUILD trial.